Poisons List Order 1998

2001. 

Acetic acid (excluding its salts and derivatives), and preparations containing more than 80% of acetic acid (CH₃COOH), for therapeutic use.

2002. 

Aciclovir for external use for the treatment of herpes labialis.

2003. 

Aloxiprin.

2003M. 

Amorolfine for topical use in preparations containing 0.25% or less of amorolfine.

2004. 

Antazoline in eye drops.

2005. 

Aspirin except –

(a) when included in Schedule 4 or 6 ; or

(b) in individually wrapped powders or sachets of granules each containing 650mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when enclosed in a primary pack that –

(i) contains not more than 12 such powders or sachets of granules; and

(ii) is labelled with one of the following warning statements:

WARNING – This medication may be dangerous when used in large amounts or for a long period.

CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.

(iii) includes in the directions for use, in capital letters not less than 1.5mm in height, the warning statements –

Consult a doctor before giving this medicine to children or teenagers with chickenpox, influenza or fever.

CAUTION – Do not give to children under 2 years of age except on doctor's advice; or

(c) in tablets or capsules each containing no other therapeutically active constituent except an effer-vescent agent when –

(i) the tablets or capsules are packed in blister or strip packaging or in a container with a child-resistant closure; and

(ii) the tablets or capsules are enclosed in a primary pack of not more than 25 tablets or capsules each containing 325mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500mg or less of aspirin; and

(iii) the primary pack is labelled with one of the warning statements set out in paragraph (b)(ii) ; and

(iv) the label on the primary pack includes in the directions for use, in the manner specified in paragraph (b)(iii) , the warning statements there set out.

2006. 

Atropine (excluding atropine methonitrate) –

(a) in preparations containing 0.25% or less of atropine; or

(b) in tablets, each containing 0.6mg of atropine sulfate, in a pack that contains 20 tablets and is labelled for treatment of organophosphorous poisoning.

2007. 

Azelaic acid in dermal preparations.

2008. 

Belladonna in preparations containing 0.25% or less of the alkaloids of belladonna.

2009. 

Benzamine when included in –

(a) lozenges, pastilles, tablets or capsules each containing 30mg or less of benzamine; or

(b) suppositories or bougies each containing 200mg or less of benzamine; or

(c) preparations for topical use, other than eye drops, containing 10% or less of local anaesthetic substances.

2010. 

Benzocaine when included in –

(a) lozenges, pastilles, tablets or capsules each containing 30mg or less of benzocaine; or

(b) suppositories or bougies each containing 200mg or less of benzocaine; or

(c) preparations for topical use, other than eye drops, containing 10% or less of local anaesthetic substances.

2011. 

Benzoyl peroxide in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide, except in preparations containing 5% or less of benzoyl peroxide.

2012. 

Benzydamine in preparations for topical use.

2013. 

Bifonazole for human use in dermal preparations.

2014. 

Bromhexine.

2015. 

Brompheniramine in oral preparations containing one or more of the following substances:

(a) an antitussive other than codeine or dihydrocodeine;

(b) an expectorant;

(c) phenylephrine;

(d) pseudoephedrine –

other than preparations for the treatment of children who have not attained the age of 2 years or preparations, supplied specifically, or labelled as suitable, for the sedation of children.

2016. 

Butylaminobenzoate when included in –

(a) lozenges, pastilles, tablets or capsules each containing 30mg or less of butylaminobenzoate; or

(b) suppositories or bougies each containing 200mg or less of butylaminobenzoate; or

(c) preparations for topical use, other than eye drops, containing 10% or less of local anaesthetic substances.

2018. 

Carbenoxolone for topical oral use.

2019. 

Carbetapentane except in preparations containing 0.5% or less of carbetapentane.

2019E. 

Cetirizine in preparations for oral use.

2020. 

Chlorbutol for human use in topical preparations containing 5% or less of chlorbutol except in preparations containing 0.5% or less of chlorbutol as a preservative.

2021. 

Chloroform (excluding its derivatives) in preparations for therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in preparations containing 0.5% or less of chloroform.

2022. 

Chlorpheniramine in oral preparations containing one or more of the following substances:

(a) an antitussive other than codeine or dihydrocodeine;

(b) an expectorant;

(c) phenylephrine;

(d) pseudoephedrine –

other than preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2023. 

Cinchocaine in preparations for topical use, other than eye drops, containing 0.5% or less of cinchocaine.

2024. 

Cinnamedrine.

2025. 

Clotrimazole for human use in dermal preparations.

2026. 

Codeine when labelled with a recommended dose not exceeding 15mg of codeine and –

(a) compounded with aspirin, paracetamol or any one of their derivatives and no other analgesic substance in tablets or capsules each containing 10mg or less of codeine when –

(i) packed in blister or strip packaging or in a container with a child-resistant closure; and

(ii) in a primary pack containing 25 or less dosage units; or

(b) compounded with aspirin, paracetamol or any one of their derivatives and no other analgesic substance in individually wrapped powders each containing 10mg or less of codeine when in a primary pack containing 25 or less dosage units; or

(c) compounded with one or more other therapeutically active substances other than an antihistamine –

(i) in divided preparations each containing 10mg or less of codeine; or

(ii) in undivided preparations each containing 0.25% or less of codeine.

2027. 

Creosote derived from wood, for human therapeutic use, except in preparations containing 3% or less of phenols included in this Schedule.

2028. 

Datura spp. in preparations containing 0.25% or less of the alkaloids of datura.

2029. 

Dexchlorpheniramine in oral preparations containing one or more of the following substances:

(a) an antitussive other than codeine or dihydrocodeine;

(b) an expectorant;

(c) phenylephrine;

(d) pseudoephedrine –

other than preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2030. 

Dextromethorphan when –

(a) in divided preparations containing 30mg or less of dextromethorphan per dosage unit and with a recommended dose not exceeding 30mg of dextromethorphan; or

(b) in undivided preparations containing 0.3% or less of dextromethorphan with a recommended dose not exceeding 30mg of dextromethorphan.

2032. 

Dicyclomine in preparations containing 0.1% or less of dicyclomine.

2033. 

Dihydrocodeine when compounded with aspirin and no other therapeutically active substances in divided preparations –

(a) containing 5mg or less of dihydrocodeine per dosage unit; and

(b) packed in blister or strip packaging or in a container with a child-resistant closure; and

(c) enclosed in primary packs containing 25 or less dosage units; and

(d) labelled with a recommended dose not exceeding 10mg of dihydrocodeine.

2034. 

Dimenhydrinate in primary packs of 10 doses or less, for the prevention or treatment of motion sickness, except in preparations for the treatment of children who have not attained 2 years of age.

2035. 

Dimethisoquin in preparations for topical use.

2037. 

Diphenhydramine in oral preparations –

(a) in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or

(b) containing one or more of the following substances:

(i) an antitussive other than codeine or dihydrocodeine;

(ii) an expectorant;

(iii) phenylephrine;

(iv) pseudoephedrine –

other than preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2038. 

Diphenylpyraline in oral preparations containing one or more of the following substances:

(a) an antitussive other than codeine or dihydrocodeine;

(b) an expectorant;

(c) phenylephrine;

(d) pseudoephedrine –

other than preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2039. 

Doxylamine in oral preparations containing one or more of the following substances:

(a) an antitussive other than codeine or dihydrocodeine;

(b) an expectorant;

(c) phenylephrine;

(d) pseudoephedrine –

other than preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2040. 

Duboisia leichhardtii in preparations containing 0.25% or less of the alkaloids of duboisia.

2041. 

Duboisia myoporoides in preparations containing 0.25% or less of the alkaloids of duboisia.

2042. 

Econazole for human use in dermal preparations.

2043. 

Erythrityl tetranitrate for therapeutic use.

2044. 

Etafedrine.

2045. 

Ether for therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in preparations containing 10% or less of ether.

2046. 

Ethoheptazine in preparations containing 1% or less of ethoheptazine.

2047. 

Ethylmorphine when –

(a) compounded with one or more other therapeutically active substances –

(i) in divided preparations containing 10mg or less of ethylmorphine per dosage unit; or

(ii) in undivided preparations containing 0.25% or less of ethylmorphine; and

(b) labelled with a recommended dose not exceeding 15mg of ethylmorphine.

2047E. 

Fexofenadine in preparations for oral use.

2048. 

Fluorides for human therapeutic use in the form of –

(a) sodium fluoride in preparations for ingestion containing 2.2mg or less of sodium fluoride per dosage unit; or

(b) preparations for topical use except –

(i) when included in Schedule 3 ; or

(ii) dentifrices containing 1 000mg/kg or less of fluoride ion; or

(iii) other preparations containing 15mg/kg or less of fluoride ion.

2049. 

Gelsemium.

2050. 

Glutaraldehyde for human therapeutic use.

2051. 

Glyceryl trinitrate except when included in Schedule 4 .

2052. 

Guaiphenesin in oral preparations for human therapeutic use except when labelled –

WARNING: This medication should not be used in children less than 2 years of age without medical advice.

2053. 

Hexachlorophane in preparations for human use containing 3% or less of hexachlorophane except –

(a) in preparations containing 0.75% or less of hexachlorophane; or

(b) in preparations for use on infants, as specified in Schedule 4 .

2054. 

Homatropine in preparations containing 0.25% or less of homatropine.

2054E. 

Hydrocortisone and Hydrocortisone acetate, but excluding other salts and derivatives, in preparations for dermal use containing 0.5 per cent or less of hydrocortisone in packs containing 30g or less of such preparations containing –

(a) no other therapeutically active substance; or

(b) an antifungal as the only other therapeutically active substance.

2055. 

Hydroquinone (excluding monobenzone and other alkyl ethers of hydroquinone included in Schedule 4 ) in preparations for human external therapeutic use or cosmetic use containing 2% or less of hydroquinone except hair preparations containing 1% or less of hydroquinone.

2056. 

8-hydroxyquinoline, and its non-halogenated derivatives, for human therapeutic use, except in preparations for external use containing 1% or less of such substances.

2057. 

Hyoscine (excluding hyoscine butylbromide) –

(a) in preparations containing 0.25% or less of hyoscine; or

(b) in transdermal applicators containing 2mg or less of hyoscine.

2057E. 

Hyoscine butylbromide as the only therapeutically active substance in divided preparations for oral use containing 10 mg or less of hyoscine butylbromide in each dosage unit in a pack containing 20 or less dosage units.

2058. 

Hyoscyamine in preparations containing 0.25% or less of hyoscyamine.

2059. 

Hyoscyamus in preparations containing 0.25% or less of the alkaloids of hyoscyamus.

2060. 

Ibuprofen in –

(a) divided preparations for oral use containing 200mg or less of ibuprofen per dosage unit in a pack containing 100 or less dosage units labelled with a recommended daily dose of not more than 1 200mg of ibuprofen; or

(b) liquid preparations for oral use which are sold in the manufacturer's original pack having a capacity of 200ml or less and in strengths of 100mg or less of ibuprofen per 5ml; or

(c) preparations for external use.

2062. 

Indomethacin in preparations for external use containing 1% or less of indomethacin.

2063. 

Iodine (excluding radiographic contrast media) –

(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose, except when labelled with one of the following in letters not less than 1.5mm high:

CAUTION – Total iodine intake may exceed recommended level when taking this preparation.

WARNING – Contains iodine – do not take when pregnant except on physician's advice.

(b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives and iodophors).

2063C. 

Ipratropium in preparations for nasal use.

2064. 

Iron compounds (excluding iron oxides when present as an excipient up to 1% in undivided preparations or up to 10mg per dosage unit in divided preparations) for human internal use except –

(a) when included in Schedule 4 ; or

(b) in divided preparations containing 5mg or less of iron per dosage unit; or

(c) in oral undivided preparations containing 0.1% or less of iron.

2064M. 

Isoconazole for human use in dermal preparations.

2065. 

Isopropamide in preparations containing 2% or less of isopropamide for dermal use.

2066. 

Isosorbide dinitrate except when included in Schedule 4 .

2066E. 

Isosorbide mononitrate except when included in Schedule 4 .

2067. 

Ketoconazole in preparations for dermal use, except in preparations containing 1 per cent or less of ketoconazole for the treatment of the scalp.

2067B. 

Ketoprofen in preparations for dermal use.

2067D. 

Levocabastine in topical eye or nasal preparations.

2068. 

Lignocaine when included in –

(a) lozenges, pastilles, tablets or capsules each containing 30mg or less of lignocaine; or

(b) suppositories or bougies each containing 200mg or less of lignocaine; or

(c) preparations for topical use, other than eye drops, containing 10% or less of local anaesthetic substances.

2069. 

Lindane in preparations for human external therapeutic use containing 2% or less of lindane.

2069M. 

Lithium for dermal use in preparations containing 1% or less of lithium.

2070. 

Lobelia except in preparations for smoking or burning.

2071. 

Lobeline except in preparations for smoking or burning.

2071J. 

Lodoxamide in preparations for ophthalmic use.

2072. 

Loperamide in packs of 8 dosage units or less, each dosage unit containing 2mg or less of loperamide.

2072C. 

Loratadine in preparations for oral use.

2074. 

Mebendazole for human therapeutic use.

2075. 

Mefenamic acid in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

2076. 

Mercuric oxide in ointments for human ocular use.

2077. 

Mercury organic compounds for topical human therapeutic use, in preparations containing 0.5% or less of mercury.

2078. 

Methoxamine except –

(a) when included in Schedule 4 ; or

(b) in preparations for external use containing 1% or less of methoxamine.

2079. 

Methoxyphenamine.

2080. 

Methylephedrine.

2081. 

Miconazole for human use in dermal preparations.

2082. 

Naphazoline.

2083. 

Naproxen in divided preparations containing 250mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

2084. 

Niclosamide for human therapeutic use.

2085. 

Nicotine for use as an aid in withdrawal from tobacco smoking, in preparations –

(a) for transdermal use; or

(b) in chewing gum.

2087. 

Noscapine.

2088. 

Nystatin in dermal preparations.

2089. 

Oxethazaine (oxetecaine) in preparations for internal use.

2090. 

Oxymetazoline.

2091. 

Papaverine except when included in Schedule 4 .

2092. 

Paracetamol for therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in individually wrapped powders or sachets of granules each containing 1 000mg or less of paracetamol as the only therapeutically active constituent, other than effervescent agents, when enclosed in a primary pack that –

(i) contains not more than 12 such powders or sachets of granules; and

(ii) is labelled with one of the following warning statements:

WARNING – This medication may be dangerous when used in large amounts or for a long period.

CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.

(iii) is not labelled for the treatment of children who have not attained the age of 7 years; or

(c) in tablets or capsules each containing 500mg or less of paracetamol as the only therapeutically active constituent, other than effervescent agents, when –

(i) the tablets or capsules are packed in blister or strip packaging or in a container with a child-resistant closure; and

(ii) the tablets or capsules are enclosed in a primary pack containing not more than 25 such tablets or capsules; and

(iii) the primary pack is labelled with one of the warning statements set out in paragraph (b)(ii); and

(iv) the primary pack is not labelled for the treatment of children who have not attained the age of 7 years.

2092M. 

Penciclovir for external use for the treatment of herpes labialis.

2093. 

Phedrazine.

2094. 

Phenazone for human external use.

2095. 

Pheniramine –

(a) in eye drops; or

(b) in oral preparations containing one or more of the following substances:

(i) an antitussive, except codeine or dihydrocodeine;

(ii) an expectorant;

(iii) phenylephrine;

(iv) pseudoephedrine –

other than in preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2096. 

Phenol, or any homologue of phenol boiling below 220°C, for human therapeutic use except –

(a) when included in Schedule 4 ; or

(b) in preparations for external use containing 3% or less of such substances.

2097. 

Phenylenediamines and alkylated phenylenediamines, for therapeutic use.

2098. 

Phenylephrine except –

(a) when included in Schedule 4 ; or

(b) in oral preparations containing 0.5 per cent or less of phenylephrine; or

(c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.

2099. 

Pholcodine –

(a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25mg of pholcodine; or

(b) when compounded with one or more other therapeutically active substances, in divided preparations containing 10mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25mg of pholcodine.

2100. 

Piroxicam in preparations for dermal use containing 1% or less of piroxicam.

2101. 

Podophyllotoxin in preparations for human external therapeutic use containing 2% or less of podophyllotoxin.

2102. 

Podophyllum resin (podophyllin) in preparations for human external therapeutic use containing 10% or less of podophyllin.

2103. 

Potassium chlorate for therapeutic use except in preparations containing 10% or less of potassium chlorate.

2104. 

Pramoxine in preparations for external use, other than eye drops, containing 1% or less of pramoxine.

2105. 

Prilocaine in preparations for topical use, other than eye drops, containing 10% or less of local anaesthetic substances.

2106. 

Procyclidine in preparations containing 5% or less of procyclidine for dermal use.

2107. 

Promethazine in oral preparations –

(a) in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or

(b) containing one or more of the following substances:

(i) an antitussive except codeine or dihydrocodeine;

(ii) an expectorant;

(iii) phenylephrine;

(iv) pseudoephedrine –

other than in preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2108. 

Propantheline in preparations for topical use.

2109. 

Pseudoephedrine in preparations (other than preparations for stimulant, appetite suppression or weight-control purposes), with a recommended daily dose of 240mg or less of pseudoephedrine –

(a) in undivided preparations containing 60mg or less of pseudoephedrine per recommended dose; or

(b) when the only therapeutically active substances in divided preparations containing 60mg or less of pseudoephedrine per recommended dose in a pack containing 30 or less dosage units; or

(c) when compounded with other therapeutically active substances; or

(d) in slow release preparations.

2110. 

Pyrantel for human therapeutic use.

2111. 

Pyrithione zinc for human therapeutic use, except –

(a) in semi-solid hair preparations; or

(b) in shampoos containing 2% or less of pyrithione zinc when labelled with the statement –

Keep out of eyes.

or the statement –

If in eyes rinse well with water.

2112. 

Salicylamide except when included in Schedule 4 .

2113. 

Silver salts for therapeutic use, except –

(a) in chewing tablets, each containing 5mg or less of silver, in a container labelled with the statement –

Overuse may stain skin or mouth.; or

(b) in a solution for human oral use, containing 0.3% or less of silver, in a container labelled with the statement –

Overuse may stain skin or mouth.; or

(c) in other preparations containing 1% or less of silver.

2114. 

Sodium cromoglycate in preparations for nasal or ophthalmic use.

2115. 

Sodium nitrite for therapeutic use (excluding when present as an excipient).

2116. 

Staphisagria except in preparations containing 0.2% or less of staphisagria.

2117. 

Stramonium in preparations containing 0.25% or less of the alkaloids of stramonium, except preparations for smoking or burning.

2118. 

Terbinafine in preparations for dermal use.

2119. 

Tetrahydrozoline.

2120. 

Thenyldiamine –

(a) in nasal preparations for topical use; or

(b) in oral preparations containing one or more of the following substances:-

(i) an antitussive other than codeine or dihydrocodeine;

(ii) an expectorant;

(iii) phenylephrine;

(iv) pseudoephedrine –

other than preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2120E. 

Tioconazole in preparations for dermal use.

2121. 

Tramazoline.

2122. 

Trimeprazine when included in oral preparations containing one or more of the following substances:

(a) an antitussive other than codeine or dihydrocodeine;

(b) an expectorant;

(c) phenylephrine;

(d) pseudoephedrine –

other than in preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2123. 

Triprolidine when included in oral preparations containing one or more of the following substances:

(a) an antitussive other than codeine or dihydrocodeine;

(b) an expectorant;

(c) phenylephrine;

(d) pseudoephedrine –

other than preparations for the treatment of children who have not attained the age of 2 years or preparations supplied specifically, or labelled as suitable, for the sedation of children.

2124. 

Tymazoline.

2125. 

Xylometazoline.

3001. 

Acepifylline in liquid oral preparations.

3002. 

Adrenaline in preparations containing more than 0.02%, but not more than 1%, of adrenaline.

3002M. 

Alclometasone in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30g or less of such preparations.

3003. 

Aminophylline in liquid oral preparations.

3004. 

Amorolfine for topical use except when included in Schedule 2 .

3005. 

Azatadine in oral preparations.

3005M. 

Beclomethasone in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the treatment of seasonal allergic rhinitis in adults and children 12 years and over.

3007. 

Brompheniramine in oral preparations except when included in Schedule 2 .

3008. 

Buclizine in oral preparations.

3008E. 

Budesonide in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the treatment of seasonal allergic rhinitis in adults and children 12 years and over.

3009. 

Chlorbutol in preparations for human use except –

(a) when included in Schedule 2 ; or

(b) in preparations containing 0.5 per cent or less of chlorbutol as a preservative.

3011. 

Chlorpheniramine in oral preparations except when included in Schedule 2 .

3012. 

Cimetidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days' supply.

3013. 

Clemastine in oral preparations.

3014. 

Clotrimazole in preparations for vaginal use.

3015. 

Codeine when –

(a) compounded with aspirin, paracetamol, salicylamide, or any of their derivatives, and no other analgesic substance, in divided preparations containing not more than 10mg of codeine per dosage unit; and

(b) labelled with a recommended dose not exceeding 15mg of codeine –

except when included in Schedule 2 .

3016. 

Cyproheptadine in oral preparations.

3017. 

Dexchlorpheniramine in oral preparations except when included in Schedule 2 .

3017S. 

Diclofenac in divided preparations for oral use containing 25mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units.

3018. 

Dihydrocodeine when –

(a) compounded with one or more other therapeutically active substances; or

(i) in divided preparations containing 10mg or less of dihydrocodeine per dosage unit; or

(ii) in undivided preparations containing 0.25% or less of dihydrocodeine; and

(b) labelled with a recommended dose not exceeding 15mg of dihydrocodeine –

except when included in Schedule 2 .

3018D. 

Di-iodohydroxyquinolone (iodoquinol) for vaginal use.

3019. 

Dimenhydrinate in oral preparations except when included in Schedule 2 .

3020. 

Dimethindene in oral preparations except when supplied specifically for use, or labelled as suitable, for the sedation of children.

3021. 

Diphenhydramine in oral preparations except when included in Schedule 2 .

3021M. 

Diphenoxylate in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate.

3022. 

Diphenylpyraline in oral preparations except when included in Schedule 2 .

3023. 

Dithranol for therapeutic use.

3023M. 

Doxylamine in oral preparations except when included in Schedule 2 .

3024. 

Econazole in preparations for vaginal use.

3025. 

Famotidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days' supply.

3027. 

Flavoxate.

3027M. 

Flunisolide in aqueous nasal sprays delivering 25 micrograms or less of flunisolide per actuation when the maximum recommended daily dose is no greater than 200 micrograms and when packed in a primary pack containing 200 actuations or less, for the treatment of seasonal allergic rhinitis in adults and children 12 years and over.

3028. 

Fluorides in dentifrices containing more than 1 000mg/kg of fluoride ion.

3028M. 

Flurbiprofen in divided preparations for topical oral use containing 10mg or less of flurbiprofen per dosage unit.

3030. 

Folic acid for human therapeutic use except in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

3031. 

Folinic acid for human therapeutic use except in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

3031M. 

Glucagon.

3031S. 

Glycopyrrolate (glycopyrronium) except when included in Schedule 4 .

3032. 

Hydrocortisone and Hydrocortisone acetate, but excluding other salts and derivatives in preparations containing 1% or less of hydrocortisone –

(a) for dermal use in packs containing 30g or less of such preparations and –

(i) containing no other therapeutically active substance; or

(ii) containing an antifungal but no other therapeutically active substance; or

(b) for rectal use, when combined with a local anaesthetic but no other therapeutically active substance –

(i) in individual preparations, in packs of 35g or less; or

(ii) in packs containing 12 or less suppositories –

except when included in Schedule 2 .

3033. 

Inositol nicotinate.

3034. 

Insulins.

3035. 

Isoconazole in preparations for vaginal use.

3035M. 

Ketoprofen in divided preparations for oral use containing 25mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

3036. 

Maldison (malathion) in preparations for human external use except in preparations containing 2 per cent or less of maldison.

3037. 

Mepyramine in oral preparations.

3038. 

Methdilazine in oral preparations.

3038J. 

Metoclopramide when compounded with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

3039. 

Miconazole for human use in topical preparations –

(a) for the treatment of oral candidiasis; or

(b) for vaginal use.

3039E. 

Minoxidil in preparations for dermal use containing 5% or less of minoxidil.

3039M. 

Mometasone in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms and when packed in a primary pack containing 200 actuations or less, for the treatment of seasonal allergic rhinitis in adults and children 12 years and over.

3040. 

Nicotine for use as an aid in withdrawal from tobacco smoking, in preparations for inhalation or sublingual use.

3040E. 

Nicotinic acid for human therapeutic use except –

(a) in preparations containing 100mg or less of nicotinic acid per dosage unit; or

(b) nicotinamide.

3040M. 

Nicotinyl alcohol except in preparations containing 100mg or less of nicotinyl alcohol per dosage unit.

3041. 

Nizatidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days' supply.

3042. 

Nystatin in preparations for topical use except when included in Schedule 2 .

3043. 

Pheniramine in oral preparations except when included in Schedule 2 .

3044. 

Phenylpropanolamine in preparations –

(a) labelled only for the relief of coughs or colds; and

(b) containing 25mg or less of phenylpropanolamine per recommended dose.

3045. 

Phenyltoloxamine in oral preparations.

3046. 

Podophyllotoxin in preparations for human external therapeutic use containing 4% or less of podophyllotoxin, except when included in Schedule 2 .

3047. 

Podophyllum resin (podophyllin) in preparations for human external therapeutic use containing 20% or less of podophyllin, except when included in Schedule 2 .

3047S. 

Prochlorperazine tablets when manufactured, packed and labelled for buccal use, only for the treatment of nausea associated with migraine, in packs containing not more than 10 tablets.

3048. 

Promethazine in oral preparations except when included in Schedule 2 .

3049. 

Quinine in preparations containing 200 milligrams or less of quinine per dosage unit for the treatment of cramp, in packs containing not more than 5 days' supply, except in preparations containing 50mg or less of quinine per recommended daily dose.

3050. 

Ranitidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days' supply.

3051. 

Salbutamol as the only therapeutically active substance –

(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or

(b) in capsules of dry powder for inhalation delivering 200 micrograms or less of salbutamol per dose.

3052. 

Santonin.

3052E. 

Selenium in preparations for oral human use with a recommended daily dose of 100 micrograms or less of selenium except in preparations for oral human use with a recommended daily dose of –

(a) 26 micrograms or less of selenium in organic form; or

(b) 52 micrograms or less of selenium in inorganic form.

3052M. 

Sodium phosphate in preparations for oral use for laxative or bowel-cleansing purposes.

3053. 

Sulfacetamide in preparations for ophthalmic use containing 10% or less of sulfacetamide.

3054. 

Terbutaline as the only therapeutically active substance in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose.

3055. 

Thenyldiamine in oral preparations except when included in Schedule 2 .

3056. 

Theophylline in liquid oral preparations.

3057. 

Tioconazole in preparations for vaginal use.

3057M. 

Tranexamic acid for the treatment of menorrhagia.

3058. 

Triamcinolone acetonide for the treatment of mouth ulcers, in preparations containing 0.1% or less of triamcinolone in a pack of 5g or less.

3059. 

Trimeprazine in oral preparations other than –

(a) preparations included in Schedule 2 ; or

(b) liquid preparations containing more than 10mg/5ml of trimeprazine.

3060. 

Triprolidine in oral preparations except when included in Schedule 2 .

40000. 

Abacavir.

40000M. 

Abciximab.

40000S. 

Acamprosate calcium.

40001. 

Acarbose.

40002. 

Acebutolol.

40003. 

Acepifylline except when included in Schedule 3 .

40004. 

Acepromazine.

40005. 

Acetanilide and alkyl acetanilides, for human therapeutic use (excluding when present as an excipient).

40005M. 

Acetarsol.

40006. 

Acetazolamide.

40007. 

Acetohexamide.

40007E. 

Acetylcarbromal.

40008. 

Acetylcholine.

40009. 

Acetylcysteine.

40009E. 

Acetyldigitoxin.

40010. 

Acetylmethyldimethyloximidophenylhydra-zine.

40010E. 

Acetylstrophanthidin.

40009S. 

Acipimox.

40011. 

Acitretin.

40012. 

Acokanthera schimperi.

40013. 

Aconite (Aconitum spp.).

40014. 

Actinomycin D (otherwise known as dactinomycin).

40015. 

Aciclovir except when included in Schedule 2 .

40016. 

Adapalene.

40017. 

Adenosine for human therapeutic use in preparations for injection.

40018. 

Adiphenine.

40019. 

Adonis (Adonis vernalis).

40020. 

Adrenaline except –

(a) when included in Schedule 3 ; or

(b) in preparations containing 0.02% or less of adrenaline.

40021. 

Adrenocortical hormones, except when separately specified in these Schedules.

40021S. 

Alatrofloxacin mesylate.

40022. 

Albendazole except –

(a) when included in Schedule 5 or 6 ; or

(b) in intraruminal implants each containing 3.85g or less of albendazole for the treatment of animals.

40022E. 

Alclofenac.

40023. 

Alclometasone except when included in Schedule 3 .

40024. 

Alcuronium salts.

40025. 

Aldosterone.

40026. 

Alendronate sodium.

40026E. 

Alendronic acid.

40026M. 

Alfacalcidol.

40027. 

Alfuzosin.

40028. 

Alglucerase.

40028M. 

Allergens.

40029. 

Allopurinol.

40030. 

Allyloestrenol.

40031. 

Alphadolone.

40032. 

Alphaxalone.

40033. 

Alprazolam.

40034. 

Alprenolol.

40035. 

Alprostadil.

40035M. 

Alseroxylon.

40035S. 

Alteplase.

40036. 

Altrenogest.

40037. 

Altretamine (hexamethylmelamine).

40038. 

Amantadine.

40039. 

Ambenonium chloride.

40040. 

Ambucetamide.

40041. 

Ambutonium bromide.

40042. 

Amcinonide.

40043. 

Amethocaine.

40044. 

Amifostine.

40045. 

Amikacin.

40046. 

Amiloride.

40047. 

3-aminobenzoic acid ethyl ester methanesulfonate.

40048. 

Aminocaproic acid.

40049. 

Aminoglutethimide.

40050. 

Aminometradine.

40051. 

Aminophenazone (amidopyrine) and derivatives for the treatment of animals.

40052. 

Aminophylline except when included in Schedule 3 .

40053. 

Aminopterin.

40054. 

4-aminopyridine for therapeutic use.

40055. 

Aminorex.

40056. 

Aminosalicylic acid.

40057. 

Amiodarone.

40058. 

Amiphenazole.

40059. 

Amisometradine.

40060. 

Amitriptyline.

40061. 

Amlodipine.

40062. 

Ammi visnaga.

40062M. 

Ammonium bromide for therapeutic use.

40063. 

Amodiaquine.

40064. 

Amorolfine except when included in Schedule 2 or 3 .

40064E. 

Amoxapine.

40065. 

Amoxycillin.

40066. 

Amphomycin.

40067. 

Amphotericin.

40068. 

Ampicillin.

40068E. 

Amrinone.

40069. 

Amsacrine.

40070. 

Amyl nitrite.

40071. 

Amylobarbitone when packed and labelled for injection.

40072. 

Amylocaine.

40073. 

Anabolic and androgenic steroidal agents except when separately specified in these Schedules.

40073M. 

Anagrelide.

40074. 

Anastrozole.

40074M. 

Ancestim.

40074S. 

Ancrod and its immunoglobulin antidote.

40075. 

Androisoxazole.

40076. 

Angiotensin amide.

40077. 

Anistreplase.

40078. 

Antazoline except when included in Schedule 2 .

40079. 

Antibiotic substances, except –

(a) when separately specified in these Schedules; or

(b) nisin.

40080. 

Antigens for human use by injection, except when separately specified in this Schedule.

40081. 

Antihistamines not elsewhere specified in this Schedule except when included in Schedule 2 or 3 .

40082. 

Antimony organic compounds for therapeutic use except when separately specified in these Schedules.

40083. 

Antisera (immunosera) for human use by injection except when separately specified in these Schedules.

40084. 

Apocynum (Apocynum spp.).

40085. 

Apomorphine.

40086. 

Apraclonidine.

40086M. 

Apronal.

40087. 

Aprotinin.

40087E. 

Arecoline.

40088. 

Arsenic for human therapeutic use except when separately specified in these Schedules.

40089. 

Aspirin –

(a) when combined with caffeine, paracetamol or salicylamide or with any of their derivatives; or

(b) for injection.

40090. 

Astemizole.

40091. 

Atamestane.

40092. 

Atenolol.

40093. 

Atipamezole.

40094. 

Atorvastatin.

40095. 

Atovaquone.

40096. 

Atracurium besylate.

40097. 

Atropine except when included in Schedule 2 .

40098. 

Auranofin.

40098M. 

Aurothiomalate sodium.

40099. 

Avilamycin except –

(a) in animal feed premixes containing 15% or less of avilamycin activity; or

(b) in animal feeds containing 50mg/kg or less of avilamycin activity.

40100. 

Avoparcin except –

(a) when packed and labelled for use as an animal feed additive; or

(b) in animal feeds.

40100S. 

Azacyclonol.

40101. 

Azaperone.

40102. 

Azapetine.

40102E. 

Azapropazone.

40102M. 

Azarabine.

40103. 

Azatadine except when included in Schedule 3 .

40104. 

Azathioprine.

40105. 

Azelaic acid except when included in Schedule 2 .

40106. 

Azithromycin.

40107. 

Azlocillin.

40108. 

Aztreonam.

40109. 

Bacampicillin.

40110. 

Bacitracin except –

(a) when included in Schedule 6 ; or

(b) in animal feeds for growth promotion containing 50mg/kg or less of antibiotic substances; or

(c) in preparations, containing 100mg/kg or less of antibiotic substances, for use as milk replacers for calves or starter rations for pigs.

40111. 

Baclofen.

40112. 

Bambermycin (flavophospholipol) except –

(a) when included in Schedule 6 ; or

(b) in animal feeds for growth promotion containing 50mg/kg or less of antibiotic substances.

40112E. 

Bamethan.

40113. 

Bamipine.

40114. 

Barbiturates, except when specified separately in these Schedules.

40114M. 

Basiliximab.

40114S. 

Becaplermin.

40115. 

Beclamide.

40116. 

Beclomethasone except when included in Schedule 3 .

40117. 

Belladonna except when included in Schedule 2 .

40118. 

Bemegride.

40119. 

Benactyzine.

40120. 

Benazepril.

40120S. 

Benethamine penicillin.

40121. 

Bendrofluazide.

40122. 

Benorylate.

40122M. 

Benoxaprofen.

40122S. 

Benperidol.

40123. 

Benserazide.

40124. 

Benzamine except when included in Schedule 2 .

40124M. 

Benzathine penicillin.

40125. 

Benzhexol.

40126. 

Benzilonium bromide.

40127. 

Benzocaine except when included in Schedule 2 .

40128. 

Benzodiazepine derivatives not elsewhere specified in these Schedules.

40129. 

Benzoyl peroxide in preparations for human therapeutic use except –

(a) when included in Schedule 2 ; or

(b) in preparations for external use containing 5% or less of benzoyl peroxide.

40129M. 

Benzoylmetronidazole.

40130. 

Benzphetamine.

40130M. 

Benzthiazide.

40131. 

Benztropine (benzatropine).

40132. 

Benzydamine except when included in Schedule 2 .

40133. 

Benzylpenicillin except when included in Schedule 6 .

40133E. 

Bepridil.

40133M. 

Beractant.

40134. 

Betahistine.

40135. 

Betamethasone.

40136. 

Betaxolol.

40137. 

Bethanechol chloride.

40138. 

Bethanidine.

40139. 

Bevantolol.

40139S. 

Bezafibrate.

40140. 

Bicalutamide.

40141. 

Bifonazole except when included in Schedule 2 .

40142. 

Biperiden.

40143. 

Bismuth compounds for cosmetic use except –

(a) bismuth citrate when incorporated in hair-colourant preparations in concentrations of 0.5% or less; or

(b) bismuth oxychloride.

40143C. 

Bismuth compounds for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.

40143E. 

Bisoprolol.

40144. 

Bleomycin.

40145. 

Bolandiol.

40146. 

Bolasterone.

40147. 

Bolazine.

40148. 

Boldenone (otherwise known as dehydrotestosterone).

40149. 

Bolenol.

40150. 

Bolmantalate.

40151. 

Boron for human therapeutic use (excluding when present as an excipient) –

(a) in preparations for internal use; or

(b) in glycerines and honeys of borax or boric acid; or

(c) in preparations for vaginal use; or

(d) in preparations for paediatric dermal use, being –

(i) dusting powders; or

(ii) other preparations containing more than 0.15% of boron; or

(e) in other preparations for dermal use containing more than 0.15% of boron except antifungal preparations.

40152. 

Botulinum toxins for human use except when separately specified in these Schedules.

40153. 

Bretylium tosylate.

40154. 

Brimonidine.

40155. 

Bromazepam.

40156. 

Bromides, inorganic, for therapeutic use except when separately specified in these Schedules.

40157. 

Bromocriptine.

40158. 

Bromoform for therapeutic use.

40159. 

Brompheniramine except when included in Schedule 2 or 3 .

40160. 

Bromvaletone.

40160S. 

Brucine for human therapeutic use.

40161. 

Brugmansia spp.

40162. 

Buclizine, except when included in Schedule 3 .

40163. 

Budesonide except when included in Schedule 3 .

40164. 

Bufexamac except –

(a) in preparations for dermal use containing 5% or less of bufexamac; or

(b) in suppositories.

40165. 

Bumetanide.

40165M. 

Buphenine.

40166. 

Bupivacaine.

40166E. 

Buserelin.

40167. 

Buspirone.

40168. 

Busulfan.

40169. 

Butacaine.

40170. 

Butyl nitrite.

40171. 

Butylaminobenzoate except when included in Schedule 2 .

40172. 

Butylchloral hydrate.

40173. 

Cabergoline.

40174. 

Calcipotriol.

40175. 

Calcitonin.

40176. 

Calcitriol.

40177. 

Calcium carbimide for therapeutic use.

40177M. 

Calcium polystyrene sulphonate.

40178. 

Calotropis (Calotropis spp.).

40179. 

Calusterone.

40180. 

Camphorated oil excluding admixtures.

40181. 

Camphotamide.

40181S. 

Candesartan cilexetil.

40182. 

Candicidin.

40183. 

Canine tick antiserum.

40184. 

Cantharidin.

40184S. 

Capecitabine.

40185. 

Capreomycin.

40186. 

Captodiame.

40187. 

Captopril.

40188. 

Capuride.

40189. 

Caramiphen.

40190. 

Carbachol.

40191. 

Carbamazepine.

40192. 

Carbaryl for human therapeutic use.

40193. 

Carbazochrome.

40194. 

Carbenicillin.

40195. 

Carbenoxolone except when included in Schedule 2 .

40196. 

Carbidopa.

40197. 

Carbimazole.

40198. 

Carbocromen.

40199. 

Carboplatin.

40199E. 

Carboprost.

40200. 

Carbromal.

40200M. 

Carbutamide.

40201. 

Carindacillin.

40201S 

Carisoprodol.

40202. 

Carmustine.

40203. 

Carnidazole.

40204. 

Carprofen.

40205. 

Carvedilol.

40206. 

Cathine.

40207. 

Cefaclor.

40208. 

Cefepime.

40208E. 

Cefetamet.

40208M. 

Cefixime.

40209. 

Cefodizime.

40209M. 

Cefonicid.

40210. 

Cefoperazone.

40211. 

Cefotaxime.

40212. 

Cefotetan.

40212M. 

Cefotiam.

40213. 

Cefoxitin.

40214. 

Cefpirome.

40215. 

Cefpodoxime.

40215S. 

Cefsulodin.

40216. 

Ceftazidine.

40216E. 

Ceftibuten.

40217. 

Ceftiofur.

40218. 

Ceftriaxone.

40219. 

Cefuroxime.

40219C. 

Celecoxib.

40219E. 

Celiprolol.

40220. 

Cephacetrile.

40221. 

Cephadroxil.

40222. 

Cephalexin.

40223. 

Cephalonium.

40224. 

Cephaloridine.

40225. 

Cephalothin.

40226. 

Cephamandole (cefamandole).

40227. 

Cephapirin.

40228. 

Cephazolin (cefazolin).

40229. 

Cephradine.

40230. 

Cerivastatin.

40230S. 

Ceruletide.

40231. 

Cetirizine except when included in Schedule 2 .

40232. 

Chenodeoxycholic acid.

40233. 

Chloral formamide.

40234. 

Chloral hydrate except in preparations for topical use containing 2% or less of chloral hydrate.

40235. 

Chloralose except when included in Schedule 6 .

40236. 

Chlorambucil.

40237. 

Chloramphenicol.

40238. 

Chlorandrostenolone.

40239. 

Chlorazanil.

40241. 

Chlorcyclizine.

40242. 

Chlordiazepoxide.

40243. 

Chlormerodrin.

40244. 

Chlormethiazole.

40245. 

Chlormezanone.

40246. 

Chloroform for use in anaesthesia.

40247. 

4-Chloromethandienone.

40248. 

2-(4-chlorophenyl)-(1,2,4) triazolo [5,1-A] isoquinoline.

40249. 

Chloroquine.

40250. 

Chlorothiazide.

40250M. 

Chlorotrianisene.

40251. 

Chloroxydienone.

40252. 

Chloroxymesterone (otherwise known as dehydrochloromethyltestosterone).

40253. 

Chlorpheniramine except when included in Schedule 2 or 3 .

40254. 

Chlorphentermine.

40255. 

Chlorpromazine.

40256. 

Chlorpropamide.

40257. 

Chlorprothixene.

40258. 

Chlorquinaldol for human topical use.

40259. 

Chlortetracycline except when included in Schedule 5 .

40260. 

Chlorthalidone.

40261. 

Chlorzoxazone.

40262. 

Cholestyramine (colestyramine) for human therapeutic use.

40263. 

Chymopapain injection for human therapeutic use.

40264. 

Ciclacillin.

40264E. 

Cidofovir.

40265. 

Cilastatin.

40266. 

Cilazapril.

40267. 

Cimetidine except when included in Schedule 3 .

40268. 

Cinchocaine except when included in Schedule 2 .

40269. 

Cinoxacin.

40270. 

Ciprofloxacin.

40271. 

Cisapride.

40272. 

Cisatracurium besylate.

40273. 

Cisplatin.

40274. 

Citalopram.

40275. 

Cladribine.

40276. 

Clanobutin.

40277. 

Clarithromycin.

40278. 

Clavulanic acid.

40279. 

Clemastine except when included in Schedule 3 .

40280. 

Clemizole.

40281. 

Clenbuterol.

40282. 

Clidinium bromide.

40283. 

Clindamycin.

40284. 

Clioquinol and other halogenated derivatives of 8-hydroxyquinoline for human topical use except when separately specified in this Schedule.

40285. 

Clobazam.

40286. 

Clobetasol.

40287. 

Clobetasone (clobetasone-17-butyrate).

40288. 

Clocortolone.

40288E. 

Clodronic acid (including sodium clodronate).

40289. 

Clofazimine.

40290. 

Clofenamide.

40291. 

Clofibrate.

40292. 

Clomiphene.

40293. 

Clomipramine.

40294. 

Clomocycline.

40295. 

Clonazepam.

40296. 

Clonidine.

40297. 

Clopamide.

40297M. 

Clopidogrel.

40298. 

Cloprostenol.

40299. 

Clorazepate.

40300. 

Clorexolone.

40301. 

Clorprenaline.

40302. 

Clostebol (otherwise known as 4-chlorotestosterone).

40303. 

Clotrimazole except when included in Schedule 2 , 3 or 6 .

40304. 

Cloxacillin.

40305. 

Clozapine.

40306. 

Codeine when compounded with one or more other therapeutically active substances –

(a) in divided preparations containing 30mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1% or less of codeine.

except when included in Schedules 2 or 3 .

40306S. 

Co-dergocrine.

40307. 

Colaspase (L-asparaginase).

40308. 

Colchicine.

40309. 

Colchicum autumnale.

40310. 

Colestipol for human internal use.

40311. 

Colfosceril palmitate for human therapeutic use.

40312. 

Colistin.

40313. 

Collagen in injectable preparations for human use.

40314. 

Convallaria (Convallaria spp.).

40315. 

Coronilla (Coronilla spp.).

40316. 

Corticosterone.

40317. 

Corticotrophin.

40318. 

Cortisone.

40318M. 

Co-trimoxazole.

40319. 

Coumarin for therapeutic use (excluding when present as an excipient).

40320. 

Crystal violet for human use, except when used as a dermal marker.

40321. 

Curare.

40322. 

Cyclandelate.

40323. 

Cyclizine.

40323E. 

Cyclobenzaprine.

40324. 

Cyclofenil.

40324M. 

Cycloheximide.

40325. 

Cyclopenthiazide.

40326. 

Cyclopentolate.

40327. 

Cyclophosphamide.

40328. 

Cyclopropane for inhalation anaesthesia.

40329. 

Cycloserine.

40330. 

Cyclosporin.

40331. 

Cyclothiazide.

40332. 

Cycrimine.

40333. 

Cymarin.

40334. 

Cyproheptadine except when included in Schedule 3 .

40335. 

Cyproterone.

40336. 

Cysteamine.

40337. 

Cytarabine.

40338. 

Dacarbazine.

40338M. 

Daclizumab.

40338S. 

Dalfopristin.

40339. 

Dalteparin (includes dalteparin sodium).

40340. 

Danaparoid (includes danaparoid sodium).

40341. 

Danazol.

40341S. 

Danthron for human use.

40342. 

Dantrolene.

40343. 

Dapsone.

40344. 

Datura spp. except –

(a) when included in Schedule 2 ; or

(b) when separately specified in this Schedule.

40345. 

Daunorubicin.

40346. 

Deanol.

40347. 

Debrisoquine.

40347E. 

Decamethonium salts.

40347M. 

Deflazacort.

40348. 

Dehydrocorticosterone.

40349. 

Demecarium bromide.

40350. 

Delavirdine (includes delavirdine mesylate).

40351. 

Demeclocycline.

40352. 

Deoxycortone.

40353. 

Desferrioxamine.

40354. 

Desflurane.

40355. 

Desipramine.

40356. 

Desirudin.

40357. 

Deslanoside.

40358. 

Deslorelin.

40359. 

Desmopressin (otherwise known as DDAVP).

40360. 

Desogestrel.

40361. 

Desonide.

40362. 

Desoxymethasone.

40363. 

Detomidine.

40364. 

Dexamethasone.

40365. 

Dexchlorpheniramine except when included in Schedule 2 or 3 .

40366. 

Dexfenfluramine.

40367. 

Dextromethorphan except when included in Schedule 2 .

40368. 

Dextropropoxyphene in –

(a) divided preparations containing 135mg or less of dextropropoxyphene per dosage unit; or

(b) liquid preparations containing 2.5% or less of dextropropoxyphene.

40369. 

Dextrorphan.

40370. 

Diazepam.

40371. 

Diazoxide.

40372. 

Dibenzepin.

40373. 

trans-4-[(3,5-dibromo-2-hydroxybenzyl)-amino] cyclohexanol hydrochloride monohydrate (otherwise known as sputolysin) except when included in Schedule 6 .

40374. 

Dichloralphenazone.

40375. 

Dichlorphenamide.

40376. 

Diclofenac except –

(a) when included in Schedule 3 ; or

(b) in preparations for dermal use.

40377. 

Dicloxacillin.

40379. 

Dicyclomine except when included in Schedule 2 .

40380. 

Didanosine.

40381. 

Dienoestrol.

40382. 

Diethazine.

40383. 

Diethylcarbamazine for human therapeutic use.

40384. 

Diethylpropion.

40385. 

Difenoxin in preparations containing, per dosage unit, 0.5mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of difenoxin.

40386. 

Diflorasone.

40387. 

Diflucortolone.

40388. 

Diflunisal.

40389. 

Digitalis (being Digitalis purpurea or Digitalis lanata).

40390. 

Digitoxin.

40391. 

Digoxin.

40392. 

Digoxin antibody.

40393. 

Dihydralazine.

40394. 

Dihydrocodeine when compounded with one or more other therapeutically active substances –

(a) in divided preparations containing not more than 100mg of dihydrocodeine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine –

except when included in Schedule 2 or 3 .

40394E. 

Dihydrogotoxine.

40395. 

Dihydrolone.

40396. 

Dihydrostreptomycin except when included in Schedule 6 .

40397. 

Di-iodohydroxyquinoline (iodoquinol) except –

(a) when included in Schedule 3 ; or

(b) for human internal use.

40398. 

Diisopropylamine dichloroacetate.

40399. 

Diltiazem.

40400. 

Dimenhydrinate except when included in Schedule 2 or 3 .

40400E. 

Dimercaprol.

40401. 

Dimethandrostanolone.

40402. 

Dimethazine.

40403. 

Dimethindene except when included in Schedule 3 .

40404. 

Dimethisoquin except when included in Schedule 2 .

40405. 

Dimethoxanate.

40406. 

Dimethyl sulfoxide for therapeutic use, except –

(a) when included in Schedule 6 ; or

(b) in in-vitro test kits.

40407. 

Dimetridazole.

40408. 

2,4-dinitrochlorobenzene for therapeutic use.

40409. 

Dinitrocresols for therapeutic use except when separately specified in these Schedules.

40410. 

Dinitronaphthols for therapeutic use except when separately specified in these Schedules.

40411. 

Dinitrophenols for therapeutic use.

40412. 

Dinitrothymols for therapeutic use.

40413. 

Dinoprost.

40414. 

Dinoprostone.

40415. 

Diperodon.

40416. 

Diphemanil methylsulfate except in preparations for dermal use.

40417. 

Diphenhydramine except when included in Schedule 2 or 3 .

40418. 

Diphenidol.

40419. 

Diphenoxylate in preparations containing, per dosage unit, 2.5mg or less of diphenoxylate, and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate, except when included in Schedule 3 .

40420. 

Diphenylpyraline except when included in Schedule 2 or 3 .

40420S. 

Diphtheria toxoid.

40421. 

Dipivefrin.

40422. 

Dipyridamole.

40423. 

Dirithromycin.

40424. 

Disophenol.

40425. 

Disopyramide.

40426. 

Distigmine.

40427. 

Disulfiram for therapeutic use.

40427M. 

Disulphamide.

40428. 

Dithiazanine except when included in Schedule 6 .

40429. 

Ditiocarb.

40430. 

Dobutamine.

40431. 

Docetaxel.

40431M. 

Dofetilide.

40432. 

Dolasetron.

40433. 

Domperidone.

40434. 

Donepezil.

40435. 

Dopamine.

40435M. 

Dopexamine.

40435S. 

Dornase.

40436. 

Dorzolamide.

40437. 

Dothiepin.

40437S. 

Doxantrazole.

40438. 

Doxapram.

40439. 

Doxazosin.

40440. 

Doxepin.

40441. 

Doxorubicin.

40442. 

Doxycycline.

40443. 

Doxylamine except when included in Schedule 2 or 3 .

40444. 

Droperidol.

40445. 

Drostanolone.

40446. 

Duboisia leichhardtii except when included in Schedule 2 .

40447. 

Duboisia myoporoides except when included in Schedule 2 .

40448. 

Dydrogesterone.

40449. 

Econazole except when included in Schedule 2 , 3 or 6 .

40450. 

Ecothiopate (includes ecothiopate iodide).

40450E. 

Ectylurea.

40451. 

Edetic acid for human therapeutic use except –

(a) in preparations containing 0.25% or less of edetic acid; or

(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or

(c) in contact lens preparations.

40451M. 

Edoxudine.

40451S. 

Edrophonium salts.

40451W. 

Efavirenz.

40452. 

Eformoterol (formoterol).

40452M. 

Eltenac.

40452S. 

Emepronium salts.

40453. 

Emetine except in preparations containing 0.2% or less of emetine.

40454. 

Enalapril.

40455. 

Enestebol.

40456. 

Enflurane for inhalation anaesthesia.

40457. 

Enoxacin.

40458. 

Enoxaparin.

40458E. 

Enoximone.

40458M. 

Enprostil.

40459. 

Enrofloxacin.

40459E. 

Entacapone.

40460. 

Ephedrine.

40461. 

Epicillin.

40462. 

Epirubicin.

40463. 

Epitiostanol.

40463E. 

Eprosartan mesylate.

40463M. 

Epoprostenol.

40463S. 

Eptifibatide.

40464. 

Ergometrine.

40465. 

Ergot.

40465E. 

Ergotamine.

40465M. 

Ergotoxine.

40466. 

Erysimum (Erysimum canescens).

40467. 

Erythromycin except –

(a) when included in Schedule 6 ; or

(b) in animal feeds for growth promotion containing 50mg/kg or less of antibiotic substances; or

(c) in preparations, containing 100mg/kg or less of antibiotic substances, for use as milk replacers for calves or starter rations for pigs.

40468. 

Erythropoietin.

40469. 

Esmolol.

40470. 

Estramustine.

40471. 

Ethacrynic acid.

40472. 

Ethambutol.

40473. 

Ethamivan.

40474. 

Ethanolamine in preparations for injection.

40475. 

Ethchlorvynol.

40476. 

Ether for use in anaesthesia.

40477. 

Ethinamate.

40478. 

Ethinyloestradiol.

40478M. 

Ethisterone.

40479. 

Ethoglucid.

40480. 

Ethoheptazine except when included in Schedule 2 .

40481. 

Ethopropazine.

40482. 

Ethosuximide.

40483. 

Ethotoin.

40484. 

Ethoxzolamide.

40485. 

Ethyl chloride for inhalation anaesthesia.

40486. 

Ethyldienolone.

40487. 

Ethylmorphine when compounded with one or more other therapeutically active substances –

(a) in divided preparations containing not more than 100mg of ethylmorphine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine –

except when included in Schedule 2 .

40488. 

Ethyloestrenol.

40489. 

Ethynodiol.

40490. 

Etidocaine.

40491. 

Etidronic acid (includes disodium etidronate) –

(a) for internal use; or

(b) in topical preparations except in preparations containing 1% or less of etidronic acid.

40492. 

Etilefrin hydrochloride.

40493. 

Etiproston.

40494. 

Etodolac.

40494M. 

Etonogestrel.

40495. 

Etoposide.

40496. 

Etretinate.

40497. 

Famciclovir.

40498. 

Famotidine except when included in Schedule 3 .

40499. 

Felodipine.

40500. 

Felypressin.

40500S. 

Fenbufen.

40501. 

Fencamfamin.

40502. 

Fenfluramine.

40502S. 

Fenoldopam.

40503. 

Fenoprofen.

40504. 

Fenoterol.

40505. 

Fenpipramide.

40506. 

Fenpiprane.

40507. 

Fenproporex.

40508. 

Fenprostalene.

40509. 

Fexofenadine except when included in Schedule 2 .

40509S. 

Fibrinolysin except for external use.

40510. 

Filgrastim.

40511. 

Finasteride.

40512. 

Flecainide.

40513. 

Fleroxacin.

40513M. 

Floctafenine.

40513S. 

Fluanisone.

40514. 

Fluclorolone.

40515. 

Flucloxacillin.

40516. 

Fluconazole.

40517. 

Flucytosine.

40518. 

Fludarabine.

40518J. 

Fludrocortisone.

40519. 

Flufenamic acid.

40520. 

Flumazenil.

40521. 

Flumethasone.

40521E. 

Flumethiazide.

40522. 

Flunisolide except when included in Schedule 3 .

40523. 

Flunixin meglumine.

40524. 

Fluocinolone acetonide.

40524E. 

Fluocinonide.

40525. 

Fluocortin.

40526. 

Fluocortolone.

40528. 

Fluorides in preparations for human ingestion, except when included in Schedule 2 .

40528S. 

Fluorometholone.

40529. 

Fluorouracil.

40530. 

Fluoxetine.

40531. 

Fluoxymesterone.

40532. 

Flupenthixol.

40533. 

Fluphenazine.

40534. 

Fluprostenol.

40534S. 

Flurandrenolone.

40535. 

Flurazepam.

40536. 

Flurbiprofen except when included in Schedule 3 .

40537. 

Fluroxene for inhalation anaesthesia.

40538. 

Fluspirilene.

40539. 

Flutamide.

40540. 

Fluticasone.

40541. 

Fluvastatin.

40542. 

Fluvoxamine.

40543. 

Follicle-stimulating hormone, except when separately specified in this Schedule.

40544. 

Follitropin alpha (recombinant human follicle-stimulating hormone).

40545. 

Follitropin beta (recombinant human follicle-stimulating hormone).

40546. 

Formebolone (formyldienolone).

40546M. 

Formestane.

40547. 

Foscarnet.

40548. 

Fosfestrol (diethylstilboestrol diphosphate).

40549. 

Fosinopril.

40550. 

Fotemustine.

40551. 

Framycetin.

40552. 

Frusemide.

40552S. 

Furaltadone.

40553. 

Furazabol.

40554. 

Furazolidone.

40555. 

Fusidic acid.

40556. 

Gabapentin.

40557. 

Galanthamine (galantamine).

40558. 

Glimepiride.

40559. 

Galanthus (Galanthus nivalis).

40560. 

Gallamine.

40561. 

Ganciclovir.

40562. 

Gemcitabine.

40563. 

Gemeprost.

40564. 

Gemfibrozil.

40565. 

Gentamicin.

40566. 

Gestodene.

40566M. 

Gestonorone.

40567. 

Gestrinone.

40567M. 

Gitalin.

40567V. 

Glatiramer acetate.

40568. 

Glibenclamide.

40569. 

Glibornuride.

40570. 

Gliclazide.

40571. 

Glimepiride.

40572. 

Glipizide.

40572M. 

Glisoxepide.

40573S. 

Glutathione for parenteral use.

40574. 

Glutethimide.

40575. 

Glyceryl trinitrate in preparations for injection.

40576. 

Glycopyrrolate (glycopyrronium) in preparations for injection.

40577. 

Glymidine.

40577S. 

GnRH vaccine.

40578. 

Gonadorelin.

40579. 

Gonadotrophic hormones except when separately specified in these Schedules.

40580. 

Goserilin acetate.

40581. 

Gramicidin.

40582. 

Granisetron.

40582M. 

Grepafloxacin.

40583. 

Griseofulvin.

40584. 

Growth hormone (including analogues) for human use.

40585. 

Guaiphenesin except –

(a) when included in Schedule 2 ; or

(b) in oral preparations when labelled –

WARNING: This medication should not be used in children less than 2 years of age without medical advice.

40586. 

Guanabenz.

40587. 

Guanacline.

40588. 

Guanethidine.

40588B. 

Guanidine.

40588E. 

Hachimycin.

40588M. 

Haematin.

40588S. 

Haemophilus influenzae vaccine.

40589. 

Halcinonide.

40590. 

Halofantrine.

40590E. 

Halofenate.

40591. 

Haloperidol.

40592. 

Halothane for inhalation anaesthesia.

40593. 

Hemerocallis (Hemerocallis flava).

40594. 

Heparin for internal use except when separately specified in this Schedule.

40594E. 

Hepatitis A vaccine.

40594M. 

Hepatitis B vaccine.

40595. 

Hetacillin.

40596. 

Hexachlorophane in –

(a) preparations for use on infants; or

(b) other preparations except –

(i) when included in Schedule 2 or 6 ; or

(ii) in preparations containing 0.75% or less of hexachlorophane.

40597. 

Hexamethonium bromide.

40597E. 

Hexetidine for human internal use.

40597M. 

Hexobendine.

40598. 

Hexocyclium methylsulfate.

40598M. 

Histamine for therapeutic use except in preparations containing 0.5% or less of histamine.

40599. 

Homatropine except when included in Schedule 2 .

40600. 

Human chorionic gonadotrophin except in pregnancy test kits.

40601. 

Hyaluronic acid in preparations for injection.

40601E. 

Hydrargaphen for internal use.

40602. 

Hydralazine.

40603. 

Hydrochlorothiazide.

40604. 

Hydrocortisone, except when included in Schedule 2 or 3 .

40605. 

Hydrocyanic acid for therapeutic use.

40606. 

Hydroflumethiazide.

40607. 

Hydroquinone (other than its alkyl ethers separately specified in this Schedule) for human therapeutic or cosmetic use except –

(a) when included in Schedule 2 ; or

(b) in hair preparations containing 1% or less of hydroquinone.

40608. 

Hydroxychloroquine.

40609. 

Hydroxyephedrine.

40609M. 

Hydroxyphenamate.

40610. 

Hydroxyprogesterone.

40611. 

Hydroxystenozol.

40612. 

Hydroxyurea.

40613. 

Hydroxyzine.

40614. 

Hygromycin except –

(a) when included in Schedule 6 ; or

(b) in animal feeds containing 50mg/kg or less of hygromycin.

40615. 

Hyoscine except when included in Schedule 2 .

40616. 

Hyoscyamine except when included in Schedule 2 .

40617. 

Hyoscyamus except when included in Schedule 2 .

40618. 

Hypothalamic-releasing factors not elsewhere specified in this Schedule.

40618S. 

Ibandronic acid.

40619. 

Ibufenac.

40620. 

Ibuprofen except when included in Schedule 2 .

40620M. 

Ibuterol.

40620S. 

Ibutilide.

40621. 

Idarubicin.

40622. 

Idoxuridine except in preparations containing 0.5% or less of idoxuridine for dermal use.

40623. 

Ifosfamide.

40623M. 

Iloprost.

40623V. 

Imiglucerase.

40624. 

Imipenem.

40625. 

Imipramine.

40625E. 

Imiquimod.

40626. 

Immunoglobulins for human parenteral use except when separately specified in these Schedules.

40627. 

Indapamide.

40628. 

Indinavir.

40629. 

Indomethacin, except when included in Schedule 2 .

40629E. 

Indoprofen.

40629M. 

Indoramin.